BOLSTER, NCT05712356: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 80 | Europe, US | LSTA1, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Oxaliplatin, Folinic acid, Fluorouracil, Placebo | Lisata Therapeutics, Inc. | Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma | 12/25 | 12/25 | | |
